Opinion|Videos|January 10, 2025
Clinical Decision-making With TKI-IO Combinations for Advanced RCC
Author(s)Viktor Grünwald, MD, PhD, Martin H. Voss, MD
Panelists discuss how clinical decision-making with TKI-IO combinations for advanced renal cell carcinoma involves evaluating factors such as efficacy, safety, patient characteristics, and the management of treatment-related toxicities to optimize patient outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5